Coeptis <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Subsidiary SNAP Biosciences Enters Licensing Partnership with Monarch Therapeutics to Enhance SNAP-CAR NK Cell Therapy in Oncology
Coeptis Therapeutics Holdings Inc., through its subsidiary SNAP Biosciences, Inc., has entered into a licensing agreement with Monarch Therapeutics Inc. to enhance the development of its SNAP-CAR NK cell therapy platform in oncology. This partnership grants SNAP Biosciences access to Monarch's innovative small-molecule adaptor technology, broadening the functionality of the Snap-Car universal CAR-based receptor platform. The collaboration aims to advance the precision, flexibility, and scalability of NK therapies, targeting multiple tumor antigens and addressing challenges in oncology treatment. Monarch Therapeutics will receive upfront licensing payments, potential development milestone payments, and royalties on net sales as part of the agreement. This initiative is expected to transform outcomes for patients with difficult-to-treat cancers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coeptis Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458972-en) on May 28, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。